AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
80.19
+0.29 (0.36%)
At close: Sep 2, 2025, 4:00 PM
80.00
-0.19 (-0.24%)
After-hours: Sep 2, 2025, 4:56 PM EDT
AstraZeneca Revenue
AstraZeneca had revenue of $14.46B in the quarter ending June 30, 2025, with 11.74% growth. This brings the company's revenue in the last twelve months to $56.50B, up 15.00% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$56.50B
Revenue Growth
+15.00%
P/S Ratio
4.37
Revenue / Employee
$608,192
Employees
92,900
Market Cap
247.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
| Thermo Fisher Scientific | 43.21B |
AZN News
- 10 hours ago - AstraZeneca: Buy This Pharma Star Now For Upside Potential - Seeking Alpha
- 3 days ago - AstraZeneca to seek approval for blood pressure drug by year-end - Reuters
- 12 days ago - Polaris Pharmacy Services Named Exclusive U.S. Distributor of AstraZeneca's FluMist® Home Service—The World's First At-Home Nasal Spray Flu Vaccine - Business Wire
- 20 days ago - The Healthcare Businesswomen's Association (HBA) Honors AstraZeneca and Viseven with 2025 ACE Awards for Workforce Innovation and Global Impact - PRNewsWire
- 22 days ago - AstraZeneca: Great Portfolio, But Not A Great Price - Seeking Alpha
- 4 weeks ago - SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes - PRNewsWire
- 4 weeks ago - Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges - WSJ
- 4 weeks ago - European drugmakers fall after Trump raises stakes over US drug price cuts - Reuters